Will new biomarkers lead to "golden age" for mental health disorder diagnosis?
This article was originally published in Clinica
Diagnosis of mental disorders, such as schizophrenia and depression, is slow, complicated and imprecise. Medtech firms are working to smooth the process with the development of definitive biomarker-based diagnostics with the aim of enabling earlier intervention and monitoring therapy to minimise side-effects. Phil Greenfield investigates
You may also be interested in...
Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.
The French start-up claims first-in-man success for heart valve “softening” treatment and plans further trials for an EU launch.
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.